AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure (AGENT-HF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01966887
Recruitment Status : Terminated
First Posted : October 22, 2013
Last Update Posted : August 29, 2017
Celladon Corporation
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris